Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Merit Medical Systems (MMSI)

Merit Medical President Joseph Wright resigns; Fred Lampropoulos reappointed President

Neutral Impact 4 of 5 leadership Written later

Merit Medical President Joseph Wright resigned effective January 3, 2025, after the company received allegations about his conduct that its independent directors investigated with outside counsel. The company says the allegations were unrelated to its operations or financial performance, and CEO Fred Lampropoulos was re-appointed as President.

Key points

  • Joseph C. Wright resigned on December 16, 2024, effective January 3, 2025, under a Separation Agreement and Release of All Claims.
  • Wright will forfeit stock options and performance stock units other than vested options and eligible PSUs as of the resignation date.
  • Fred P. Lampropoulos, age 75, the company's CEO since 1987, was re-appointed President; the filing states his compensation has not changed.
  • The filing says the allegations were unrelated to Merit's operations or financial performance; Lampropoulos is Wright's brother-in-law.

The filing

CompanyMerit Medical Systems (MMSI)
Form8-K, current report
Filed with the SECDec 19, 2024, 4:52 PM ET
Accession number0000856982-24-000105

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:05 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on December 19, 2024.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.